Literature DB >> 34088349

YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition.

Xiangyuan Luo1,2, Mengdie Cao1,2, Fan Gao1,2, Xingxing He3,4.   

Abstract

BACKGROUND: N6-methyladenosine (m6A) modification, as the most abundant RNA modification, widely participates in the physiological process and is involved in multiple disease progression, especially cancer. YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) is a pivotal m6A "reader" protein, which has been reported in multiple cancers. However, the role and molecular mechanism of YTHDF1 in HCC are still not fully elucidated.
METHODS: Based on various bioinformatics databases, q-RT PCR, western blot, and a tissue microarray containing 90 HCC samples, we examined the expression of YTHDF1 in HCC. Then, we applied the loss-of-function experiments to explore the role of YTHDF1 in HCC by in vitro and in vivo assays. Finally, we performed the gene set enrichment analysis (GSEA) to predict the potential signaling pathway of YTHDF1 involved in HCC and further verified this prediction.
RESULTS: YTHDF1 was overexpressed in HCC and associated with HCC grade. Depletion of YTHDF1 markedly impaired the proliferation, migration, invasion, and cell cycle process of HCC cells. Mechanistically, YTHDF1 promoted the growth of HCC cells via activating the PI3K/AKT/mTOR signaling pathway. Moreover, we also demonstrated that the epithelial-mesenchymal transition (EMT) mediated the promoting effect of YTHDF1 on the migration and invasion of HCC cells.
CONCLUSIONS: YTHDF1 contributes to the progression of HCC by activating PI3K/AKT/mTOR signaling pathway and inducing EMT.

Entities:  

Keywords:  EMT; Liver cancer; PI3K/AKT/mTOR; YTHDF1; m6A

Year:  2021        PMID: 34088349     DOI: 10.1186/s40164-021-00227-0

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN: 2162-3619


  46 in total

1.  N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.

Authors:  Xiao Wang; Boxuan Simen Zhao; Ian A Roundtree; Zhike Lu; Dali Han; Honghui Ma; Xiaocheng Weng; Kai Chen; Hailing Shi; Chuan He
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

Review 2.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

Review 3.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

Review 4.  Dynamic RNA Modifications in Gene Expression Regulation.

Authors:  Ian A Roundtree; Molly E Evans; Tao Pan; Chuan He
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

5.  Healing the wounds of Vietnam.

Authors:  L C Kolb
Journal:  Hosp Community Psychiatry       Date:  1982-11

Review 6.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.

Authors:  Xiang-Yuan Luo; Kong-Ming Wu; Xing-Xing He
Journal:  J Exp Clin Cancer Res       Date:  2021-05-18

7.  Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma.

Authors:  Furong Liu; Lu Qin; Zhibin Liao; Jia Song; Chaoyi Yuan; Yachong Liu; Yu Wang; Heze Xu; Qiaofeng Zhang; Youliang Pei; Hongwei Zhang; Yonglong Pan; Xiaoping Chen; Zhanguo Zhang; Wanguang Zhang; Bixiang Zhang
Journal:  Exp Hematol Oncol       Date:  2020-05-25

Review 8.  m6A-binding proteins: the emerging crucial performers in epigenetics.

Authors:  Yanchun Zhao; Yuanfei Shi; Huafei Shen; Wanzhuo Xie
Journal:  J Hematol Oncol       Date:  2020-04-10       Impact factor: 17.388

Review 9.  Emerging agents and regimens for hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2019-10-26       Impact factor: 17.388

Review 10.  Roles of METTL3 in cancer: mechanisms and therapeutic targeting.

Authors:  Chengwu Zeng; Wanxu Huang; Yangqiu Li; Hengyou Weng
Journal:  J Hematol Oncol       Date:  2020-08-27       Impact factor: 17.388

View more
  14 in total

1.  METTL14-mediated N6-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma.

Authors:  Zhuonan Liu; Tianshui Sun; Chiyuan Piao; Zhe Zhang; Chuize Kong
Journal:  Cell Commun Signal       Date:  2022-03-19       Impact factor: 5.712

Review 2.  m6A binding protein YTHDF2 in cancer.

Authors:  Xiaomin Chen; Xiangxiang Zhou; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-04-05

3.  HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis.

Authors:  Tao Qin; Ying Xiao; Weikun Qian; Xueni Wang; Mengyuan Gong; Qiqi Wang; Rui An; Liang Han; Wanxing Duan; Qingyong Ma; Zheng Wang
Journal:  Cell Death Dis       Date:  2022-04-21       Impact factor: 9.685

4.  Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.

Authors:  Meng-Hui Zhang; Jun Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 5.  The Role of m6A RNA Methylation in Cancer: Implication for Nature Products Anti-Cancer Research.

Authors:  Na Song; Kai Cui; Ke Zhang; Jie Yang; Jia Liu; Zhuang Miao; Feiyue Zhao; Hongjing Meng; Lu Chen; Chong Chen; Yushan Li; Minglong Shao; Jinghang Zhang; Haijun Wang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 6.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

7.  The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.

Authors:  Sha Qin; Gaoming Liu; Haoer Jin; Xue Chen; Jiang He; Juxiong Xiao; Yan Qin; Yitao Mao; Luqing Zhao
Journal:  Aging (Albany NY)       Date:  2022-08-12       Impact factor: 5.955

Review 8.  The role of RNA modification in hepatocellular carcinoma.

Authors:  Qiang Feng; Dongxu Wang; Tianyi Xue; Chao Lin; Yongjian Gao; Liqun Sun; Ye Jin; Dianfeng Liu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 9.  Function and clinical significance of N6-methyladenosine in digestive system tumours.

Authors:  Junchao Huang; Yingjie Shao; Wendong Gu
Journal:  Exp Hematol Oncol       Date:  2021-07-10

10.  PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.

Authors:  Peng Du; Kaifeng Luo; Guoyong Li; Jisheng Zhu; Qi Xiao; Yong Li; Xingjian Zhang
Journal:  Int J Med Sci       Date:  2021-08-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.